Search

Displaying results 1061 - 1070 of 8468 in total
  1. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

  2. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions.

  3. Drug

    Calcium lactate

    go.drugbank.com/drugs/DB13231
    ApprovedVet approved

    Approved by the FDA as a direct food substance affirmed as generally recognized as safe, calcium lactate is used as a firming agent, flavoring agent, leavening agent, stabilizer, and thickener [L2741]. … Calcium lactate is also found in daily dietary supplements as a source of calcium. It is also available in various hydrate forms, where calcium lactate pentahydrate is the most common.

  4. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  5. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

  6. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S. … It has one chiral center and is the R-stereoisomer.[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.

  7. Drug

    Cod liver oil

    go.drugbank.com/drugs/DB11321
    ApprovedNutraceuticalVet approved

    Also being a rich source of vitamin A and D, cod liver oil can be taken orally as daily supplements. … It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria.

  8. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

  9. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs

  10. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. … [A179422] Most recently, in June 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.